BI 3032950

BI 3032950 is an investigational small molecule drug developed by Boehringer Ingelheim for the treatment of ulcerative colitis, a chronic inflammatory bowel disease. It is currently in phase II clinical trials and is being studied in adults with moderate to severe ulcerative colitis who have not responded to or have discontinued previous treatments. The drug can be administered intravenously (IV) or subcutaneously (SC), with IV used during induction and SC for maintenance therapy. While the precise mechanism of action has not been fully disclosed, Boehringer Ingelheim describes BI 3032950 as a TREM-1 antagonist, suggesting it targets the triggering receptor expressed on myeloid cells 1 (TREM-1), which plays a role in amplifying inflammatory responses[2][7][1]. As of now, it remains an unapproved new molecular entity under active investigation.